Arcturus Therapeutics Holdings Inc.

16.14+0.1200+0.75%Vol 1.33M1Y Perf -53.32%
Jun 24th, 2022 16:00 DELAYED
BID15.11 ASK16.08
Open16.43 Previous Close16.02
Pre-Market- After-Market15.84
 - -  -0.30 -1.86%
Target Price
47.44 
Analyst Rating
Hold 2.78
Potential %
193.93 
Finscreener Ranking
     34.53
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
     39.91
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
     36.31
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
8.33 
Earnings Rating
Strong Sell
Market Cap426.39M 
Earnings Date
8th Aug 2022
Alpha0.03 Standard Deviation0.32
Beta2.79 

Today's Price Range

15.0316.58

52W Range

11.7065.00

5 Year PE Ratio Range

-7.10-2.80

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
19.82%
1 Month
-5.78%
3 Months
-40.62%
6 Months
-59.59%
1 Year
-53.32%
3 Years
64.86%
5 Years
105.87%
10 Years
-77.91%

TickerPriceChg.Chg.%
ARCT16.140.12000.75
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
3.00
3.00
0.19
0.37
-68.70
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
-
-1 264.20
-1 257.00
-354.20
-84.18
RevenueValueIndustryS&P 500US Markets
15.48M
0.59
-13.02
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.29-1.94-50.39
Q04 2021-1.77-1.4716.95
Q03 2021-1.40-2.05-46.43
Q02 2021-1.99-2.07-4.02
Q01 2021-1.16-2.15-85.34
Q04 2020-0.90-1.25-38.89
Q03 2020-0.47-0.92-95.74
Q02 2020-0.53-0.55-3.77
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.84-52.07Negative
9/2022 QR-1.65-135.71Negative
12/2022 FY-6.66-45.10Negative
12/2023 FY2.00-52.72Negative
Next Report Date8th Aug 2022
Estimated EPS Next Report-1.84
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.33M
Shares Outstanding26.42K
Shares Float17.04M
Trades Count13.53K
Dollar Volume21.25M
Avg. Volume1.01M
Avg. Weekly Volume1.51M
Avg. Monthly Volume813.42K
Avg. Quarterly Volume711.21K

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock closed at 16.14 per share at the end of the most recent trading day (a 0.75% change compared to the prior day closing price) with a volume of 1.33M shares and market capitalization of 426.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Arcturus Therapeutics Holdings Inc. CEO is Joseph E. Payne.

The one-year performance of Arcturus Therapeutics Holdings Inc. stock is -53.32%, while year-to-date (YTD) performance is -56.39%. ARCT stock has a five-year performance of 105.87%. Its 52-week range is between 11.7 and 65, which gives ARCT stock a 52-week price range ratio of 8.33%

Arcturus Therapeutics Holdings Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 1.93, a price-to-sale (PS) ratio of 22.99, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.21%, a ROC of -58.18% and a ROE of -73.88%. The company’s profit margin is -84.18%, its EBITDA margin is -1 257.00%, and its revenue ttm is $15.48 Million , which makes it $0.59 revenue per share.

Of the last four earnings reports from Arcturus Therapeutics Holdings Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.84 for the next earnings report. Arcturus Therapeutics Holdings Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Arcturus Therapeutics Holdings Inc. is Hold (2.78), with a target price of $47.44, which is +193.93% compared to the current price. The earnings rating for Arcturus Therapeutics Holdings Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arcturus Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arcturus Therapeutics Holdings Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.04, ATR14 : 1.95, CCI20 : -18.11, Chaikin Money Flow : 0.09, MACD : -1.11, Money Flow Index : 64.46, ROC : -17.40, RSI : 48.17, STOCH (14,3) : 49.78, STOCH RSI : 1.00, UO : 56.65, Williams %R : -50.22), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arcturus Therapeutics Holdings Inc. in the last 12-months were: Padmanabh Chivukula (Sold 58 100 shares of value $2 571 008 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (33.33 %)
3 (37.50 %)
4 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (44.44 %)
4 (50.00 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
2 (22.22 %)
1 (12.50 %)
2 (25.00 %)
Summary RatingHold
2.78
Moderate Buy
2.50
Moderate Buy
2.50

Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-2020.

CEO: Joseph E. Payne

Telephone: +1 858 900-2660

Address: 10628 Science Center Drive, San Diego 92121, CA, US

Number of employees: 88

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

67%33%

Bearish Bullish

63%37%

TipRanks News for ARCT

Wed, 25 May 2022 08:40 GMT Arcturus Therapeutics (ARCT) Gets a Sell Rating from Goldman Sachs

- TipRanks. All rights reserved.

Wed, 20 Apr 2022 16:05 GMT Arcturus Therapeutics (ARCT) Receives a Hold from H.C. Wainwright

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 10:22 GMT Arcturus Therapeutics (ARCT) Receives a Sell from Robert W. Baird

- TipRanks. All rights reserved.

Wed, 26 Jan 2022 12:46 GMT Arcturus Therapeutics (ARCT) Gets a Hold Rating from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits